了解索拉费尼布诱导的心血管毒性:机制和治疗影响
Jue Li1, Lusha Zhang2, Teng Ge2
1Engineering Research Center of Brain Health Industry of Chinese Medicine, Key Laboratory of Pharmacodynamics and Material Basis of Chinese Medicine of Shaanxi Administration of Traditional Chinese Medicine, Pharmacology of Chinese medicine, Shaanxi University of Chinese Medicine, Xianyang, 712046, People's Republic of China.
Drug design, development and therapy
|March 25, 2024
概括
索拉菲尼布是一种氨酸激酶抑制剂 (TKI),有效治疗像HCC和RCC这样的癌症,但会导致心血管问题. 了解这些机制,包括内皮功能障碍和铁亡,是控制副作用和改善癌症治疗的关键.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 铁氨酸激酶抑制剂 (TKIs) 向血管内皮生长因子受体 (VEGFR) 用于癌症治疗.
- 索拉菲尼布是一种VEGFR和RAF抑制剂,用于肝细胞癌 (HCC) 和细胞癌 (RCC).
- 包括索拉菲尼布在内的TKIs与显著的心血管不良影响有关,例如高血压和心脏功能障碍.
研究的目的:
- 探索索拉费尼布诱导的心血管不良影响背后的机制.
- 讨论减轻这些副作用的潜在治疗策略.
- 为了突出索拉费尼布的心血管毒性,疗效和新出现的因素,如糖分解之间的联系.
主要方法:
- 关于索拉费尼布心血管毒性的机制的文献综述.
- 分析潜在的治疗策略,包括抗氧化剂和氨酸-血管素系统抑制剂.
- 对索拉芬尼布诱导的糖解和耐药性的新兴研究进行了审查.
主要成果:
- 索拉费尼布诱导的心血管毒性包括内皮功能障碍,线粒体功能障碍,内质网膜应激,自和铁.
- 高血压是与索拉费尼布疗效相关的显著副作用.
- 新出现的证据表明,索拉费尼布诱导的糖解,耐药性和心血管毒性之间存在联系.
结论:
- 了解索拉芬尼的心血管毒性机制对于优化癌症治疗至关重要.
- 制定有针对性的策略可以帮助最大限度地降低与sorafenib治疗相关的心血管风险.
- 需要进一步的研究,以充分阐明糖解在索拉费尼布毒性和耐药性的作用.
更多相关视频
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
424
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
424
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
162
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
162
01:22Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
01:22Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.8K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.8K
01:26Heart Failure Drugs: Inotropic Agents
578
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
578